EPZ6438 Tazemetostat EPZ-6438 CAS: 1403254-99-8

CAS NO: 1403254-99-8
EPZ6438 Tazemetostat EPZ-6438
Chemical Name: Tazemetostat (EPZ-6438)
Molecular Formula: C34H44N4O4
Formula Weight: 572.74
CAS No.: 1403254-99-8
Description Review
Description

EPZ6438 (also known as Tazemetostat or EPZ-6438) is a small molecule inhibitor that has been developed to target the enhancer of zeste homolog 2 (EZH2) protein. This product has shown potential as a therapeutic agent for various types of cancer, including lymphoma and solid tumors.

Chemical name: N-[(4,6-Dimethyl-2-pyridinyl)methyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazole-5-carboxamide

Molecular formula: C34H44F3N5O2

Formula weight: 559.76 g/mol

CAS No: 1403254-99-8

Top ten keywords from Google:

  1. EZH2 inhibitor
  2. Cancer therapy
  3. Epigenetic modifier
  4. Small molecule drug
  5. Histone methyltransferase inhibitor
  6. Clinical trials
  7. Therapeutic potential
  8. Oncology research
  9. Gene expression regulation
  10. Lymphoma treatment

Synonyms:

  • Tazemetostat
  • EPZ-6438
  • N-[(4,6-Dimethyl-2-pyridinyl)methyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazole-5-carboxamide

Health benefits of this product: The primary health benefit of EPZ6438 is its potential ability to inhibit the EZH2 protein, which is an epigenetic regulator that is over-expressed in various types of cancer cells. By inhibiting EZH2, EPZ6438 may restore gene expression and prevent cancer progression.

Potential effects: Due to its ability to inhibit EZH2, EPZ6438 has shown promise as a therapeutic agent for various types of cancers, including lymphoma, breast cancer, prostate cancer, and many others. In preclinical studies, EPZ6438 has been shown to significantly reduce tumor growth and increase survival rates in animal models.

Product mechanism: EPZ6438 works by selectively inhibiting the activity of EZH2, which is a histone methyltransferase responsible for adding methyl groups to histones, thereby repressing the transcription of tumor suppressor genes. By inhibiting EZH2, EPZ6438 can prevent the methylation of histones, leading to the re-expression of silenced tumor suppressors.

Safety: Although EPZ6438 has shown promising results in preclinical studies, its safety profile in humans is still being studied. In clinical trials, some adverse effects have been reported, including fatigue, nausea, and vomiting, among others. However, these side effects were generally mild and well-tolerated.

Side effects: As with any medication, there is a risk of side effects when taking EPZ6438. Some potential side effects include headache, fatigue, dizziness, nausea, vomiting, and diarrhea. If you experience any of these symptoms while taking EPZ6438, you should consult your healthcare provider immediately.

Dosing information: The optimal dosing regimen for EPZ6438 has not yet been established. However, current clinical trials are investigating doses ranging from 200mg to 1800mg per day. Patients should follow their healthcare provider's instructions regarding dosing and administration.

Conclusion: EPZ6438 is a promising new EZH2 inhibitor that has shown significant potential as an anti-tumor agent in preclinical studies. Although its safety and efficacy in humans are still being evaluated, early results suggest that it may be a valuable addition to the arsenal of cancer therapies. As further research is conducted, EPZ6438 may prove to be a valuable tool in the fight against cancer

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code
Message Us